Overview

Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
0
Participant gender:
All
Summary
Aims: 1. To pilot an randomized, controlled trial (RCT) to assess the effectiveness of the commonly prescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellulose (bulking-agent) and of the patient CBT based self-management website. 2. To assess the level of support needed for patients using the patient CBT based self-management website for IBS (i.e., initial 30 minute telephone support session with a nurse and email support or not).
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Hazel Everitt
Collaborator:
National Institute for Health Research, United Kingdom
Treatments:
Alverine
Mebeverine
Criteria
Inclusion Criteria:

- Patients aged 16 to 60 years with symptoms of irritable bowel syndrome that fulfill
the Rome III criteria

Exclusion Criteria:

- Atypical symptoms (unexplained weight loss, rectal bleeding)

- Diagnosis of inflammatory bowel disease, coeliac disease or peptic ulcer disease

- Pregnant or breast feeding

- Currently taking or allergy to mebeverine or methylcellulose